Navigation Links
Valeant Pharmaceuticals To Syndicate Incremental Loans
Date:9/14/2012

MONTREAL, Sept. 14, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced plans to syndicate an additional $1,000,000,000 of incremental term B loans under its existing senior secured credit facilities.  The incremental term B loans will be used to provide a portion of the financing for Valeant's anticipated acquisition of all of the outstanding common stock of Medicis Pharmaceutical Corporation (NYSE: MRX). The incremental term B loans will have a seven year term and are expected to have terms that are substantially similar to the Company's existing Term Loan B facility. The incremental term B loans are expected to close in the first half of 2013, concurrent with the closing of the transaction. The Company also intends, subject to market and other conditions, to raise approximately $500,000,000 of unsecured debt for general corporate purposes, including acquisitions.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Forward-looking Statements

This press release may contain forward-looking statements.  Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements which include statements regarding our plans to syndicate incremental term loans and the proposed terms thereof and our expectation as to when and if the incremental term loan facility will close, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report filed with the Securities and Exchange Commission ("SEC") and risks and uncertainties as detailed from time to time in the Company's filings with the SEC and the Canadian Securities Administrators ("CSA"), which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Announces Management Change
2. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
3. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
4. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
5. Valeant Pharmaceuticals To Host Investor Day
6. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
7. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
8. Isis Pharmaceuticals Completes Redemption Of 2 5/8% Convertible Subordinated Notes Due 2027
9. Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial
10. Gerri Henwood Joins Actinium Pharmaceuticals as Chief Development Officer
11. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... 28, 2017 The U.S. Food and ... treat adults with moderate-to-severe eczema (atopic dermatitis). Dupixent ... controlled adequately by topical therapies, or those for ... be used with or without topical corticosteroids. ... to approving new and innovative therapies for patients ...
(Date:3/28/2017)... PHOENIX , March 28, 2017  Today, ... Pharmacy released a new white paper to ... use of latex in healthcare. Specifically, there is substantial confusion ... fact, the FDA has urged manufacturers to drop the term ... labels, because of the challenge to ensure a product is ...
(Date:3/28/2017)... March 28, 2017 The global ... landscape, with the top three companies, namely Shimadzu Corporation, ... a significant 49% of the overall market in 2015, ... vendor landscape is intensely competitive and has few players, ... market. These factors have restricted the entry of new ...
Breaking Medicine Technology:
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... in Wethersfield, Conn., has relocated its corporate headquarters to a new, more expansive ... , In October 2016, Qualidigm purchased a distressed office building in Wethersfield, ...
(Date:3/28/2017)... Billerica, MA (PRWEB) , ... March 28, 2017 ... ... instrument for direct measurement of corrosive ions found in power plant water and ... plant components such as turbines and boilers, leading to extensive maintenance and unplanned ...
(Date:3/28/2017)... ... , ... Columbus OH. Dr. Justin Harper, Founder of Juvly Aesthetics in Ohio ... country to sit on the 2017 National Advisory Board for Allergan’s Facial Aesthetics National ... helped propel the clinic from a small start-up to number 78 in the country ...
(Date:3/28/2017)... ... 28, 2017 , ... Prominant bariatric surgeon and well-known weight-loss ... offer the recently FDA-approved Obalon Balloon System to his patients. The Obalon is ... already comprehensive list of weight-loss services. Dr. Liu is proud to announce ...
(Date:3/28/2017)... ... March 28, 2017 , ... With expansion and efficiency in ... early March. , The seed processing plant opened in Marshallville in 2006, and a ... new office allows opportunity for transition of Patten Seed operations to the Middle Georgia ...
Breaking Medicine News(10 mins):